Monday, November 20, 2023 1:20:22 AM
If Elite had bought them we wouldn't have 3 needle movers on the horizon, we would probably just be about to or just barely paid off the debt.
You are just completely making this up without any justification in reality. Why would this be true? Pivotal bioequivalence for OxyContin reported Jan 2017. Pivotal bioequivalence for Needle Mover 2 reported in Jan 2018. We've been hearing about Needle Mover 3 for just as long. That's not a lot movement on this pipeline in the past six years, if this is what we traded for his ownership of Adderall.
You probably didn't buy a ton of shares at $0.03 or $0.04
In fact I bought almost all my shares in that range, before I ever heard of Nasrat Hakim and back when there were less than 400 million shares outstanding. The only things the company has now that it didn't back then is 3x outstanding shares and generic Adderall, which Hakim finagled half ownership. If you want to thank someone for saving the company, thank Jim Huang from SunGen, who got us into Adderall. If he hadn't done that, who knows where we would be.
Now that it is close to $0.15 do you expect someone to sell those to you now at $0.03 or $0.04? You shouldn't but who knows given you think Nasrat should do the equivalent for the Adderall rights he bought.
This analogy doesn't even make sense. I never said any price. I said he should name the price and the terms and make it happen. A better analogy would be if I hired an agent to acquire a property on my behalf and they came back and told me I couldn't afford it but they could so they bought it instead, while refusing to tell me the purchase price.
BTW, I don't care that he is CEO. Being CEO doesn't mean he has to fund or support the company with his personal money. In fact a successful CEO doesn't use any of his own money because he can sell investors on supporting the company.
Yeah, that's what I said. He should have done what CEO's do and gotten off his ass and told this story to people with money to invest and then bought the rights on behalf of the company. Whatever the cost, it would have been less than giving him half of our profits year after year. WTF? Carter said we couldn't afford it so I bought it instead? What a lazy dick. Why do you think I'm asking him to use his personal money to do anything? I'm doing the opposite. I want his personal money OUT of the public company, the sooner the better. And even if you don't care, it is highly irregular to have a CEO who intermingles his private business with the critical operations of his public company. This is a problem. It is a barrier to our acquisition, and it needs to stop.
.
#FreeSequestOx
#FreeTacoForShareholders
Recent ELTP News
- Form 8-K - Current report • Edgar (US Regulatory) • 04/02/2026 12:05:23 PM
- Elite Pharmaceuticals Announces Commercial Launch of Methadone Hydrochloride Tablets • Newsfile • 04/02/2026 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/17/2026 10:10:32 PM
- Elite Pharmaceuticals, Inc. Reports Financial Results for the Third Quarter of Fiscal Year 2026 (three months ended December 31, 2025) and Provides Conference Call Information • Newsfile • 02/17/2026 09:19:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/17/2026 09:06:15 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/11/2026 09:35:26 PM
- Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss Third Quarter 2026 Financial Results on February 18, 2026 • Newsfile • 02/11/2026 09:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/13/2026 09:35:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/14/2025 10:10:23 PM
- Elite Pharmaceuticals, Inc. Reports Financial Results for the Second Quarter of Fiscal Year 2026 Ended September 30, 2025 and Provides Conference Call Information • Newsfile • 11/14/2025 09:19:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:11:38 PM
- Form 8-K/A - Current report: [Amend] • Edgar (US Regulatory) • 11/12/2025 10:19:32 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/12/2025 12:15:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/10/2025 12:15:46 PM
- Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss Second Quarter 2026 Financial Results on November 17, 2025 • Newsfile • 11/10/2025 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/26/2025 09:17:39 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 08/22/2025 01:39:01 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/14/2025 08:37:09 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/08/2025 08:35:45 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/25/2025 10:05:07 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/10/2025 08:17:22 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/08/2025 08:15:11 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 07/08/2025 02:58:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/30/2025 08:27:51 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 06/30/2025 08:05:59 PM
